Janus Henderson Group PLC lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 31.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,000,731 shares of the medical device company’s stock after selling 451,754 shares during the quarter. Janus Henderson Group PLC owned 1.10% of DexCom worth $149,949,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of DXCM. Royal London Asset Management Ltd. raised its position in DexCom by 3.4% during the 2nd quarter. Royal London Asset Management Ltd. now owns 34,164 shares of the medical device company’s stock worth $5,159,000 after purchasing an additional 1,115 shares during the last quarter. KBC Group NV raised its position in DexCom by 5.4% during the 2nd quarter. KBC Group NV now owns 47,208 shares of the medical device company’s stock worth $7,074,000 after purchasing an additional 2,433 shares during the last quarter. Wealthcare Advisory Partners LLC bought a new position in DexCom during the 2nd quarter worth $37,000. Janney Montgomery Scott LLC raised its position in DexCom by 23.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 12,360 shares of the medical device company’s stock worth $1,852,000 after purchasing an additional 2,357 shares during the last quarter. Finally, HWG Holdings LP bought a new position in DexCom during the 2nd quarter worth $157,000. 96.13% of the stock is currently owned by hedge funds and other institutional investors.
DXCM stock opened at $153.50 on Thursday. The stock has a 50-day simple moving average of $150.23. DexCom, Inc. has a 1-year low of $105.05 and a 1-year high of $161.30. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The company has a market cap of $14.00 billion, a price-to-earnings ratio of 511.67 and a beta of 0.80.
Several research analysts have recently weighed in on DXCM shares. Zacks Investment Research lowered DexCom from a “buy” rating to a “hold” rating and set a $163.00 price objective for the company. in a research report on Monday. Raymond James lifted their price objective on DexCom from $150.00 to $172.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. ValuEngine lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. UBS Group lifted their price objective on DexCom from $140.00 to $160.00 and gave the stock a “neutral” rating in a research report on Thursday, August 1st. Finally, BTIG Research reissued a “hold” rating on shares of DexCom in a research report on Thursday, August 1st. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. DexCom presently has a consensus rating of “Buy” and a consensus price target of $166.75.
In other news, EVP Steven Robert Pacelli sold 3,597 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $116.71, for a total value of $419,805.87. Following the completion of the sale, the executive vice president now directly owns 72,570 shares in the company, valued at approximately $8,469,644.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Quentin S. Blackford sold 8,874 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $118.95, for a total value of $1,055,562.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,665 shares of company stock valued at $7,344,275. 1.80% of the stock is currently owned by company insiders.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: Why is the price target of stocks important?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.